Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)

Trial Profile

caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms BONSAI
  • Most Recent Events

    • 16 Feb 2019 Results (n=11, data from Jan 2018 to Sep 2018) presented at the 2019 Genitourinary Cancers Symposium
    • 10 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium
    • 19 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top